Chemo-Free hope for lymphoma patients: new combo shows promise
NCT ID NCT03474744
First seen May 13, 2026 · Last updated Jun 11, 2026 · Updated 7 times
Summary
This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial includes 36 adults with newly diagnosed or relapsed lymphoma who need treatment but cannot have or have failed local therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Elblandkliniken Stiftung & Co. KG, Innere Medizin II
Riesa, 01589, Germany
-
Gemeinschaftspraxis, Fachärzte für Innere Medizin
Mannheim, 68161, Germany
-
Johanniter GmbH, Johanniter-Krankenhaus
Bonn, 53113, Germany
-
Kath. Karl-Leisner-Klinikum gGmbH, Betriebsstätte Wilhelm-Anton-Hospital
Goch, 47574, Germany
-
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
Mutlangen, 73557, Germany
-
Klinikum der Universität München, Medizinische Klinik und Poliklinik III
München, 83177, Germany
-
MVZ Goslar, MVZ Onkologische Kooperation Harz
Goslar, 38642, Germany
-
Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I
Vienna, 1190, Austria
-
Rotes Kreuz Krankenhaus, Klinik für Interdisziplinäre Onkologie
Kassel, 34121, Germany
-
Sana Klinikum Offenbach GmbH
Offenbach, 63069, Germany
-
St. Josef-Hospital, Medizinische Klinik I
Bochum, 44791, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
Universitätsklinik PIUS Hospital, Innere Medizin
Oldenburg, 26121, Germany
-
Universitätsklinikum Halle, Klinik und Poliklinik für Innere Medizin
Halle, 06120, Germany
-
Universitätsmedizin Mannheim, III. Medizinische Klinik
Mannheim, 68167, Germany
-
Universitätsmedizin Rostock
Rostock, 18051, Germany
-
ÜBAG MVZ Dr. Vehling-Kaiser GmbH
Landshut, 84036, Germany
-
ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing
Dingolfing, 84113, Germany
Conditions
Explore the condition pages connected to this study.